Ocumetics Technology Corp. (OTCFF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ocumetics Technology Corp. (OTCFF) trades at $0.31. Ocumetics Technology Corp. is a research and product development company focused on designing and producing advanced lenses. Market cap: $17.75M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for OTCFF: OTCFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OTCFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OTCFF: 1/1 perspectives are bearish.
How is this calculated? →Ocumetics Technology Corp. (OTCFF) Healthcare & Pipeline Overview
Ocumetics Technology Corp. is a Canadian research and development company specializing in advanced intraocular lenses, most notably the Bionic Lens, aimed at disrupting the vision correction market. Operating within the medical instruments and supplies sector, Ocumetics seeks to provide a permanent solution to vision impairment, though it faces competition from established players.
What Is the Investment Thesis for OTCFF?
Ocumetics Technology Corp. presents a high-risk, high-reward investment opportunity centered on its Bionic Lens technology. The company's success depends on the successful development, regulatory approval, and commercialization of this innovative product. Key value drivers include positive clinical trial results demonstrating the safety and efficacy of the Bionic Lens, securing regulatory approvals in key markets such as the United States and Europe, and establishing strategic partnerships for manufacturing and distribution. The company's current market capitalization of $17.75M reflects the early stage of development and the inherent risks associated with bringing a novel medical device to market. Upcoming catalysts include the progression of clinical trials and potential announcements regarding regulatory submissions. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the vision correction market. The company's negative P/E ratio of -12.20 indicates that it is not currently profitable, highlighting the speculative nature of this investment.
Based on FMP financials and quantitative analysis
OTCFF Key Highlights
- Ocumetics Technology Corp. focuses on research and development of the Bionic Lens, an intraocular lens designed to eliminate the need for corrective eyewear.
- The company is headquartered in Calgary, Canada, indicating its presence in the North American market.
- Ocumetics operates in the Medical - Instruments & Supplies industry, a sector characterized by innovation and technological advancements.
- The company's market capitalization is $0.02 billion, reflecting its early stage and potential for growth.
- Ocumetics has a beta of 0.23, suggesting relatively low volatility compared to the overall market.
Who Are OTCFF's Competitors?
OTCFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOQ Bioqual, Inc. | $32.50 | +0.00% | $29.07M | 38 |
| CANSF Atlas Energy Corp. | $0.10 | -13.93% | $36.98M | 44 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OTCFF's Key Strengths?
- Innovative Bionic Lens technology.
- Potential to disrupt the vision correction market.
- Strong focus on research and development.
- Experienced leadership team.
What Are OTCFF's Weaknesses?
- Early stage of development.
- Dependence on a single product.
- Limited financial resources.
- Lack of established market presence.
What Could Drive OTCFF Stock Higher?
- Publication of clinical trial results for the Bionic Lens.
- Potential regulatory submissions to the FDA and EMA.
- Continued research and development efforts to improve the Bionic Lens technology.
- Exploration of strategic partnerships with ophthalmic companies.
- Securing additional funding for research and development.
What Are the Key Risks for OTCFF?
- Financial-distress signal — its Altman Z-Score of -35.42 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could delay or halt the development of the Bionic Lens.
- Regulatory hurdles could prevent the commercialization of the Bionic Lens.
- Competition from established players in the vision correction market.
- Limited financial resources could hinder the company's growth.
- Technological obsolescence could render the Bionic Lens obsolete.
What Are the Growth Opportunities for OTCFF?
- Successful Clinical Trials: Positive results from clinical trials are crucial for demonstrating the safety and efficacy of the Bionic Lens. Successful trials will pave the way for regulatory approvals and commercialization. The global market for vision correction is estimated to be worth billions of dollars, and a successful product could capture a significant share. The timeline for clinical trials and regulatory approvals is estimated to be several years, with potential market entry in the late 2020s.
- Regulatory Approvals: Securing regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is essential for commercializing the Bionic Lens. These approvals validate the safety and efficacy of the device and allow it to be marketed to healthcare providers and patients. The regulatory approval process can take several years and requires substantial investment in data collection and documentation. Successful approvals would open up significant market opportunities for Ocumetics.
- Strategic Partnerships: Forming strategic partnerships with established players in the ophthalmic industry can accelerate the development and commercialization of the Bionic Lens. These partnerships can provide access to manufacturing capabilities, distribution networks, and marketing expertise. Collaborating with companies that have existing relationships with ophthalmologists and optometrists can facilitate market adoption. The timeline for establishing strategic partnerships is ongoing, with potential announcements in the coming years.
- Expanding Product Portfolio: While the Bionic Lens is the primary focus, Ocumetics could explore expanding its product portfolio to address other vision-related conditions or develop complementary technologies. This could include developing lenses for specific patient populations or creating diagnostic tools for assessing vision health. Diversifying the product portfolio can reduce the company's reliance on a single product and create new revenue streams. The timeline for expanding the product portfolio is dependent on the success of the Bionic Lens and the availability of resources.
- Geographic Expansion: After securing regulatory approvals in key markets such as the United States and Europe, Ocumetics can expand its geographic reach to other regions, including Asia and Latin America. These regions have large populations with unmet needs for vision correction. Adapting the Bionic Lens technology to meet the specific needs of different markets and navigating local regulatory requirements will be essential for successful geographic expansion. The timeline for geographic expansion is dependent on the availability of resources and the regulatory landscape in each region.
What Opportunities Does OTCFF Have?
- Growing demand for vision correction solutions.
- Potential for strategic partnerships.
- Expanding into new geographic markets.
- Developing complementary technologies.
What Threats Does OTCFF Face?
- Competition from established players.
- Regulatory hurdles.
- Clinical trial failures.
- Technological obsolescence.
What Are OTCFF's Competitive Advantages?
- Proprietary Bionic Lens technology.
- Patents protecting its innovations.
- Potential first-mover advantage in the intraocular lens market.
- Strong focus on research and development.
What Does OTCFF Do?
Ocumetics Technology Corp., headquartered in Calgary, Canada, is a research and product development company focused on revolutionizing vision correction. The company's core product is the Bionic Lens, an expandable intraocular lens designed to be implanted in the eye, potentially eliminating the need for glasses or contact lenses. Founded with the vision of providing a permanent solution to vision impairment, Ocumetics has dedicated its resources to the research, development, and eventual commercialization of this technology. The Bionic Lens is designed to fit within the natural lens compartment of the eye, offering a potential improvement over traditional corrective methods. Ocumetics operates primarily in the medical instruments and supplies sector, targeting individuals seeking advanced vision correction solutions. The company's success hinges on the successful completion of clinical trials, regulatory approvals, and eventual market adoption of the Bionic Lens. Ocumetics faces competition from established players in the ophthalmic industry, including companies that manufacture and distribute traditional contact lenses, eyeglasses, and perform laser vision correction surgeries. The company's ability to differentiate itself through innovative technology and demonstrate superior clinical outcomes will be critical to its long-term success.
What Products and Services Does OTCFF Offer?
- Designs intraocular lenses.
- Develops the Bionic Lens, an expandable lens for vision correction.
- Conducts research and development in the field of ophthalmology.
- Aims to eliminate the need for glasses and contact lenses.
- Seeks regulatory approvals for its Bionic Lens technology.
- Focuses on commercializing advanced vision correction solutions.
How Does OTCFF Make Money?
- Develops and patents innovative lens technology.
- Seeks regulatory approval for its products.
- Plans to manufacture and distribute the Bionic Lens.
- Potentially licenses its technology to other companies.
What Industry Does OTCFF Operate In?
Ocumetics Technology Corp. operates within the medical instruments and supplies industry, a segment of the healthcare sector driven by technological innovation and an aging global population. The market for vision correction is substantial, encompassing eyeglasses, contact lenses, and refractive surgeries. Ocumetics aims to disrupt this market with its Bionic Lens technology, offering a potential alternative to existing solutions. The industry is characterized by intense competition, with established players holding significant market share. Companies like BIOQ, CANSF, CBSTF, DSOL, and ITHUF represent some of the competitive landscape. Success in this industry requires significant investment in research and development, clinical trials, and regulatory approvals.
Who Are OTCFF's Key Customers?
- Individuals seeking vision correction.
- Ophthalmologists and optometrists.
- Hospitals and eye clinics.
- Potential licensing partners in the ophthalmic industry.
Company Profile
Ocumetics Technology Corp. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Dean E. Burns. OTCFF has traded publicly since 2021.
Ocumetics Technology Corp. (OTCFF) Valuation Context
Valued at $17.75M, OTCFF is classified as a micro-cap stock.
ROE 196%Key Financial Metrics
Return on equity for Ocumetics Technology Corp. stands at 196.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -11.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -14.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Ocumetics Technology Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.42 places it in the distress zone, a signal of elevated financial risk.
OTCFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Ocumetics' future prospects, suggesting that leadership sees potential growth ahead.
- Community sentiment has shifted positively, with increased discussions around the company's innovative technology in the ophthalmic space.
- The market has responded favorably to recent announcements about advancements in their product pipeline, enhancing investor optimism.
- Increased media coverage highlights Ocumetics' unique position in a niche market, attracting attention from both retail and institutional investors.
Bear Case
- Concerns about the company's ability to scale operations effectively have been raised, leading to skepticism among some investors.
- Recent social sentiment reflects a divided community, with notable bearish discussions questioning the sustainability of current innovations.
- Insider selling activity in the past month has raised red flags, suggesting potential lack of confidence from some executives in the company's immediate future.
- Market perception is clouded by broader economic uncertainties impacting the healthcare sector, which could affect Ocumetics' growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OTCFF Latest News
No recent news available for OTCFF.
OTCFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OTCFF.
Price Targets
Wall Street price target analysis for OTCFF.
OTCFF MoonshotScore
What does this score mean?
The MoonshotScore rates OTCFF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dean E. Burns
CEO
Dean E. Burns serves as the CEO of Ocumetics Technology Corp. His background includes experience in corporate management and strategic development, with a focus on emerging technologies. He has been involved in guiding the company's vision and strategic direction, particularly in the development and commercialization of the Bionic Lens technology. His expertise lies in navigating the complexities of the medical device industry and securing funding for research and development initiatives. He is responsible for overseeing the company's operations and ensuring that it meets its strategic objectives.
Track Record: Under Dean Burns' leadership, Ocumetics Technology Corp. has focused on advancing the Bionic Lens technology through various stages of development. Key milestones include securing patents for the technology and initiating clinical trials. His strategic decisions have been centered on attracting investment and building a team of experts to support the company's goals. He has also been instrumental in establishing relationships with potential partners and navigating the regulatory landscape.
OTCFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ocumetics Technology Corp. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Potential for price manipulation.
- Higher risk of fraud.
- Lower liquidity compared to major exchanges.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Patents on Bionic Lens technology.
- Initiation of clinical trials.
- Presence of a CEO and management team.
- Company website and investor relations materials.
- Focus on research and development.
OTCFF Healthcare Stock FAQ
What does Ocumetics Technology Corp. do?
Ocumetics Technology Corp. is a research and development company focused on creating the Bionic Lens, an intraocular lens designed to eliminate the need for glasses or contact lenses. The company aims to revolutionize the vision correction market by providing a permanent solution to vision impairment. Ocumetics is currently in the clinical trial phase, seeking to demonstrate the safety and efficacy of its Bionic Lens technology. The company's success depends on securing regulatory approvals and establishing strategic partnerships to commercialize its product.
What do analysts say about OTCFF stock?
As of March 18, 2026, there is no readily available analyst consensus on OTCFF due to its OTC listing and speculative nature. The company's valuation is primarily driven by the potential of its Bionic Lens technology. Investors should carefully consider the risks associated with investing in OTC stocks and conduct thorough due diligence before making any investment decisions. The company's growth prospects are tied to the successful development and commercialization of the Bionic Lens.
What are the main risks for OTCFF?
The main risks for Ocumetics Technology Corp. include clinical trial failures, regulatory hurdles, competition from established players in the vision correction market, limited financial resources, and technological obsolescence. Clinical trial failures could delay or halt the development of the Bionic Lens. Regulatory hurdles could prevent the commercialization of the Bionic Lens. Competition from companies like BIOQ, CANSF, CBSTF, DSOL, and ITHUF could limit the company's market share. Limited financial resources could hinder the company's growth. Technological obsolescence could render the Bionic Lens obsolete.
What are the key factors to evaluate for OTCFF?
Evaluate OTCFF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does OTCFF data refresh on this page?
OTCFF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OTCFF's recent stock price performance?
Ocumetics Technology Corp. (OTCFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Bionic Lens technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OTCFF overvalued or undervalued right now?
Valuing Ocumetics Technology Corp. (OTCFF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OTCFF?
Before investing in Ocumetics Technology Corp. (OTCFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry a higher degree of risk than stocks listed on major exchanges.